Tenapanor

CHEMBL3304485 Phase 4 معتمد Small molecule

Half-Life

—

Bioavailability

—

Protein Binding

—

Molecular Weight

1145.0 g/mol

LogP

5.1

Phase

4

Tenapanor is a minimally absorbed inhibitor of the intestinal sodium/hydrogen exchanger NHE3 that reduces sodium and phosphate absorption from the gut, approved for irritable bowel syndrome with constipation (IBS-C) and for reduction of serum phosphorus in adults with chronic kidney disease on dialysis. By inhibiting NHE3-mediated paracellular phosphate transport, it significantly lowers serum phosphate levels in dialysis patients. Its local intestinal action with minimal systemic absorption provides a targeted approach with reduced systemic adverse effects.

الوزن الجزيئي

1145,0000 g/mol

LogP

5,10

TPSA

235,00 Å²

قاعدة ليبينسكي للخمسة

راسب

المجالات العلاجية

Parkinson's Disease Chronic Kidney Disease Type 2 Diabetes

Pharmacokinetics (PK)

Pharmacodynamics (PD)

البنية ثنائية الأبعاد

SVG PNG

Cite this structure

Embed this structure

SMILES

CN1Cc2c(Cl)cc(Cl)cc2[C@H](c2cccc(S(=O)(=O)NCCOCCOCCNC(=O)NCCCCNC(=O)NCCOCCOCCNS(=O)(=O)c3cccc([C@@H]4CN(C)Cc5c(Cl)cc(Cl)cc54)c3)c2)C1

InChI

InChI=1S/C50H66Cl4N8O10S2/c1-61-31-43(41-27-37(51)29-47(53)45(41)33-61)35-7-5-9-39(25-35)73(65,66)59-15-19-71-23-21-69-17-13-57-49(63)55-11-3-4-12-56-50(64)58-14-18-70-22-24-72-20-16-60-74(67,68)40-10-6-8-36(26-40)44-32-62(2)34-46-42(44)28-38(52)30-48(46)54/h5-10,25-30,43-44,59-60H,3-4,11-24,31-34H2,1-2H3,(H2,55,57,63)(H2,56,58,64)/t43-,44-/m0/s1

Molecular Formula

C50H66Cl4N8O10S2

HBD / HBA

6 / 14

الروابط القابلة للدوران

29

الذرات الثقيلة

74

No targets recorded

Target interaction data is not yet available for this drug.

No interactions recorded

Drug interaction data is not yet available for this compound.

No side effects recorded

Side effect data is not yet available for this drug.

الأسئلة الشائعة

Tenapanor is a minimally absorbed inhibitor of the intestinal sodium/hydrogen exchanger NHE3 that reduces sodium and phosphate absorption from the gut, approved for irritable bowel syndrome with constipation (IBS-C) and for reduction of serum phosphorus in adults with chronic kidney disease on dialysis. By inhibiting NHE3-mediated paracellular phosphate transport, it significantly lowers serum phosphate levels in dialysis patients. Its local intestinal action with minimal systemic absorption provides a targeted approach with reduced systemic adverse effects.

Yes, Tenapanor is an approved drug. It has reached clinical phase 4. It is classified as a Small molecule.

{# References & Data Sources section for drug detail pages. Renders standard pharmacological database links plus the drug's data_sources field. #}

References & Data Sources

ChEMBL — European Bioinformatics Institute (EBI). CHEMBL3304485. Open-access bioactivity database.
PubChem — National Center for Biotechnology Information (NCBI). CID 71587953. Chemical information database.

Data aggregated from publicly available pharmacological databases. Last updated 2026-03-28.

PillFYI

هل تبحث عن معلومات ملائمة للمرضى؟

Tenapanor على PillFYI

البنية

بيانات سريعة

الصيغة الجزيئية: C50H66Cl4N8O10S2
المرادفات: 2

روابط خارجية

Cite

BibTeX, APA, MLA, Chicago, IEEE, Harvard

إخلاء المسؤولية الطبية

This content is for educational and informational purposes only. It is not a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making medication decisions.

Data sources: ChEMBL, PubChem, DailyMed.